HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and raises the price target from $11 to $21.
February 20, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Y-mAbs Therapeutics and increases the price target from $11 to $21.
The upgrade in the price target from $11 to $21 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Y-mAbs Therapeutics' future performance. This significant increase in the price target is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100